A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–TNF Therapy

Kremer, JM, Emery, P, Camp, HS et al. (7 more authors) (2016) A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–TNF Therapy. Arthritis & Rheumatology, 68 (12). pp. 2867-2877. ISSN 2326-5191

Abstract

Metadata

Authors/Creators:
  • Kremer, JM
  • Emery, P
  • Camp, HS
  • Friedman, A
  • Wang, L
  • Othman, AA
  • Khan, N
  • Pangan, AL
  • Jungerwirth, S
  • Keystone, EC
Copyright, Publisher and Additional Information: © 2016 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Dates:
  • Published: December 2016
  • Accepted: 23 June 2016
  • Published (online): 7 July 2016
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 22 Jul 2016 11:19
Last Modified: 15 Jan 2018 17:06
Published Version: https://doi.org/10.1002/art.39801
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.39801

Share / Export

Statistics